Results 71 to 80 of about 35,072 (188)

Adalimumab

Annales de Dermatologie et de Vénéréologie, 2019
  +8 more sources

Qualification and Application of a Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometric Method for the Determination of Adalimumab in Rat Plasma

Pharmaceutics, 2018
A liquid chromatography–quadrupole time-of-flight (Q-TOF) mass spectrometric method was developed for early-stage research on adalimumab in rats. The method consisted of immunoprecipitation followed by tryptic digestion for sample preparation and ...
Yuri Park, Nahye Kim, Jangmi Choi, Min-Ho Park, Byeong ill Lee, Seok-Ho Shin, Jin-Ju Byeon, Young G. Shin   +7 more
doaj   +1 more source

Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab

Pharmacology Research & Perspectives, 2020
FKB327 was approved by the European Medicines Agency as a biosimilar to European‐authorized adalimumab (Humira®; AbbVie Inc). Adalimumab is a monoclonal antibody, binding and inhibiting tumor necrosis factor (TNF)‐α with use indicated for several immune ...
Stefan Schreiber, Katsuhiko Yamamoto, Rafael Muniz, Takafumi Iwura   +3 more
doaj   +1 more source

Relentless Placoid Chorioretinitis: A Case Series of Successful Tapering of Systemic Immunosuppressants Achieved with Adalimumab

Case Reports in Ophthalmology, 2019
Background: Adalimumab, a human anti-tumor necrosis factor-ɑ monoclonal antibody, was recently reported to be effective in lowering the risk of recurrence of noninfectious uveitis.
Shotaro Asano, Rie Tanaka, Hidetoshi Kawashima, Toshikatsu Kaburaki   +3 more
doaj   +1 more source

Adalimumab Monotherapy in a Patient with Psoriatic Arthritis Associated with Chronic Renal Failure on Hemodialysis: A Case Report and Literature Review

Clinical Medicine Insights: Case Reports, 2012
We report a patient with psoriatic arthritis (PsA) who was successfully treated with adalimumab even while under hemodialysis therapy for associated chronic renal failure. Flow cytometry of circulating lymphocytes revealed an obvious decrease in both Th1
Yasuhiro Shimojima, Masayuki Matsuda, Wataru Ishii, Shu-ichi Ikeda   +3 more
doaj   +1 more source

The TNFα-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients

Frontiers in Immunology
Treatment efficacy of patients receiving anti-TNF antibodies is limited by the formation of anti-drug antibodies. These are observed in most adalimumab-treated rheumatoid arthritis patients, despite the adjuvant-free and human sequence-derived nature of ...
Mateusz Makuch, Josine van Beek, Josine van Beek, Carla A. Wijbrandts, Marja Aalbers, Philippe Stas, Alexander B. Meijer, Anja ten Brinke, Theo Rispens, Paul Peter Tak, Paul Peter Tak, Gertjan Wolbink, Gertjan Wolbink, Janine Schuurman, Paul W. H. I. Parren, Paul W. H. I. Parren, S. Marieke van Ham, S. Marieke van Ham   +17 more
doaj   +1 more source

Update on the management of inflammatory bowel disease: specific role of adalimumab

Clinical and Experimental Gastroenterology, 2011
Luisa Guidi, Daniela Pugliese, Alessandro ArmuzziInternal Medicine and Gastroenterology, Complesso Integrato Columbus, Università Cattolica del Sacro Cuore, Rome, ItalyAbstract: Anti-tumor necrosis factor alpha (TNF-a) medications are a class ...
Guidi L, Pugliese D, Armuzzi A
doaj  

Experience of using adalimumab in treating sight-threatening paediatric or adolescent Behcet’s disease-related uveitis

Journal of Ophthalmic Inflammation and Infection, 2019
Purpose To report the clinical outcomes of adalimumab in treating refractory Behcet’s disease (BD)-related uveitis in paediatric or adolescent patients. Methods Retrospective review of five paediatric or adolescent patients with BD-related uveitis with a
Mary Ho, Li Jia Chen, Helena P. Y. Sin, Lawrence P. L. Iu, Marten Brelen, Assunta C. H. Ho, Timothy Y. Y. Lai, Alvin L. Young   +7 more
doaj   +1 more source

Pyoderma Gangrenosum in a Patient with Crohn’s Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature

Clinics and Practice
Background: Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that frequently occurs in association with systemic diseases such as inflammatory bowel disease (IBD).
Fotios S. Fousekis, Konstantinos Mpakogiannis, Emmanouil Karampinis, Ioanna Nefeli Mastorogianni, Dimitrios K. Christodoulou, Marina Papoutsaki, Evanthia Zampeli, Konstantinos H. Katsanos   +7 more
doaj   +1 more source

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Pharmaceuticals
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ages ...
Wenting Zhang, Ziqi Xu, Yamin Shu, Sainan Shu, Qilin Zhang   +4 more
doaj   +1 more source